Cardiome shares battered after FDA places clinical hold on vernakalant Phase III trial

22 Oct 2010

• By Nancy Faigen

Shares of Cardiome Pharma sank 25% in premarket trading on 21 October after the company announced that an unexpected case of cardiogenic shock forced investigators at its partner, Astellas Pharma, to halt enrollment for a key Phase III confirmatory study of the atrial fibrillation drug vernakalant injection.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

18 Apr 2025

• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

15 Apr 2025

• By Alaric DeArment

BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

15 Apr 2025

• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.